These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32028428)

  • 1. Efficacy and safety of bivalirudin vs heparin in patients with coronary heart disease undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Liu XQ; Luo XD; Wu YQ
    Medicine (Baltimore); 2020 Feb; 99(6):e19064. PubMed ID: 32028428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Zhang S; Gao W; Li H; Zou M; Sun S; Ba Y; Liu Y; Cheng G
    Int J Cardiol; 2016 Apr; 209():87-95. PubMed ID: 26882192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.
    Saad M; Nairooz R; Rashed A; Abdelaziz HK; Mentias A; Abbott JD
    Cardiovasc Revasc Med; 2017 Sep; 18(6):418-424. PubMed ID: 28291727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis.
    Mushahid H; Shah SA; Farhan SH; Shuja MH; Balasingam K; Siddiqui AA; Hameed I; Akram K; Mushahid S; Usman MS
    Am J Cardiovasc Drugs; 2024 May; 24(3):385-398. PubMed ID: 38683263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.
    Cavender MA; Sabatine MS
    Lancet; 2014 Aug; 384(9943):599-606. PubMed ID: 25131979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
    Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
    J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes of Bivalirudin Versus Heparin in Elderly Patients Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Meng S; Xu J; Guo L; Huang R
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):101-111. PubMed ID: 32100149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of bivalirudin versus heparin in patients with diabetes mellitus undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Zhang J; Yang X
    Medicine (Baltimore); 2017 Jul; 96(29):e7204. PubMed ID: 28723739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions.
    Grajek S; Michalak M; Gwizdała A; Araszkiewicz A; Grygier M; Hiczkiewicz J; Lesiak M
    Kardiol Pol; 2018; 76(4):740-749. PubMed ID: 29350380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
    Xu H; Wang B; Yang J; Ma S; Xie X
    PLoS One; 2017; 12(1):e0169951. PubMed ID: 28095453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
    BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalirudin versus heparin in patients with acute myocardial infarction: A meta-analysis of randomized trials.
    Ferrante G; Valgimigli M; Pagnotta P; Presbitero P
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):378-89. PubMed ID: 25913723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
    Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of bivalirudin versus heparin in transradial coronary interventions.
    Kheiri B; Rao SV; Osman M; Simpson TF; Barbarawi M; Zayed Y; Dhillon HN; Alkhouli M; Golwala H; Zahr F; Bhatt DL; Stone GW; Cigarroa JE
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1240-1248. PubMed ID: 32091668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention.
    Shah R; Rogers KC; Matin K; Askari R; Rao SV
    Am Heart J; 2016 Jan; 171(1):14-24. PubMed ID: 26699596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
    Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
    Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials.
    Lipinski MJ; Lhermusier T; Escarcega RO; Baker NC; Magalhães MA; Torguson R; Suddath WO; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2014; 15(6-7):315-22. PubMed ID: 25440505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.